Publications
Specialty
Search
Oncology
06/18/2024
Subgroup analysis results from the DELLphi-301 study found that tarlatamab showed promising efficacy with favorable benefit-risk profile among patients with previously treated small-cell lung cancer, regardless of baseline brain metastases.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
06/18/2024
Dr. Chan’s winning submission, “Socioeconomic disparities and the prognostic value of coronary inflammatory risk from routine coronary CT angiography: The Oxford Risk Factors and Non-Invasive Imaging (ORFAN) study,” investigates the relationship between coronary inflammation and social deprivation status, which is considered a driver for cardiovascular disease.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
06/18/2024
JACC Incoming Editor-in-Chief Harlan M. Krumholz, MD, SM, FACC, said, the goal of the report card is to promote accountability and catalyze action that finally addresses this national tragedy. “Our study reveals that Black Americans, because of their higher cardiovascular mortality rates compared with White Americans, have suffered almost 800,000 excess deaths," he said.
EP Lab Digest
06/18/2024
In this video, Lauren Sell, MSN, APRN, CPNP, discusses her presentation from Heart Rhythm 2024.
EP Lab Digest
06/18/2024
Megan LaBreck, PharmD, BCPS, CACP, and Kristen Campbell, PharmD, BCPS, CPP, discuss the role of the pharmacist in electrophysiology, current challenges in antiarrhythmic drug therapy, and pharmacist-led educational intervention.
Wound Care
06/18/2024
HealPrecisely is a start-up finding traction by rapidly adopting innovations in wound care and pioneering mobile technologies.
The Dermatologist
06/18/2024
During the Revolutionizing Atopic Dermatitis (RAD) June 2024 meeting, presenters showcased how ruxolitinib cream, a topical Janus kinase 1/JAK2 inhibitor, is the first US Food and Drug Administration and European Commission-approved repigmentation treatment for nonsegmental vitiligo in patients aged 12 years and older.
Vascular Disease Management
06/18/2024
Penumbra announced the CE Mark and European launch of BMX™81 and BMX™96. These devices are designed for neurovascular management of ischemic and hemorrhagic stroke and are Penumbra’s most advanced neuro access offerings.
This announcement further expands the company’s neuro portfolio in Europe, following the news in early May when Penumbra launched three new RED™ reperfusion catheters (RED 43, RED 72 with SENDit™ Technology, and RED 78).
Wounds, Wound Care
06/17/2024
HMP Global’s Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) partnered with the Wound Care Collaborative Community (WCCC) to host the inaugural Driving Innovation in Wound Care Summit, addressing public policy challenges related to assuring patients receive access to wound-healing therapies.
Journal of Invasive Cardiology, CardioVascular
06/17/2024
The objective of the study was to examine and compare the hemodynamic impact of saddle vs non-saddle pulmonary embolism in a selected patient population.
EP Lab Digest
06/17/2024
Intuitive motorization for greater control and high-power (25 kW [1]) for state-of-the-art image quality supports complex vascular needs and a full range of clinical procedures
Automated workflows contribute to greater flexibility and independence for clinicians, providing more time to focus on achieving the best possible outcomes for patients
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
06/17/2024
The new mobile C-arm with expanded capabilities is designed to meet complex vascular needs, but also a range of clinical procedures such as cardiac interventions, pain management and urology.
EMSWorld
06/17/2024
Dr. Vivek Murthy demanded that Congress require social media companies to put a label on their apps, mirroring the warnings required on cigarettes and other products containing tobacco.
EMSWorld
06/17/2024
Topics covered at the Federal Interagency Committee on EMS include the USFA’s EMS Branch, the Department of Transportation's National Roadway Safety Strategy, and funding from the Hospital Preparedness Program.
Oncology
06/17/2024
Based on results from the phase 3 KEYNOTE-868/NRG-GY018 trial, the FDA has approved pembrolizumab plus carboplatin and paclitaxel followed by single-agent pembrolizumab for patients with primary advanced or recurrent endometrial cancer.
Psych Congress Network
06/17/2024
Time for a pop quiz!
Rheumatology & Arthritis
06/17/2024
A first biologic disease-modifying antirheumatic drug showed similar efficacy among psoriatic arthritis patients with a low number of affected joints as among those with a high number.
Oncology, Journal of Clinical Pathways
06/17/2024
According to results from the phase 3 KRYSTAL-12 trial, adagrasib improved survival and response compared to docetaxel among patients with previously treated KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular, Vascular Disease Management
06/17/2024
“The sobering reality is that many of these amputations can be prevented with early detection. Understanding risk factors, and symptoms and working collaboratively with other disciplines is key. Through the MISA initiative, we want to promote education, awareness, and the use of the latest advancements to treat PAD,” says Dr. Pedro Martinez Clark, founder of Amavita Health.
Oncology
06/17/2024
In this video, a panel of experts discuss the management of patients with HER2-positive metastatic breast cancer, including updated results from the DESTINY-Breast03 trial.